HC Wainwright Has Positive Forecast for GPCR FY2027 Earnings

Chronological Source Flow
Back

AI Fusion Summary

HC Wainwright raised its FY2027 EPS estimate for Structure Therapeutics (GPCR) to $2.27, down from $2.34, while keeping a Buy rating and a $100 target price. Future forecasts show modest EPS growth through FY2030.
19/03 07:32 defenseworld.net
3 Πηγές
19/03 07:48 defenseworld.net
19/03 08:34 defenseworld.net
Comments
Loading...
0